CSF3R-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patients

Key points:• In patients with CSF3R-mutated chronic neutrophilic leukemia(CNL), white blood cell response (≥50% reduction from baseline count) was not significantly different between those who received ruxolitinib-based combination therapy and those treated with hydroxyurea.• ASXL1 and/or SETBP1 mutations were observed in 78% of patients and were associated with early blast transformation (BT) and inferior overall survival (OS).• Allogeneic stem cell transplantation significantly improved OS in patients with CSF3Rmutated CNL.